(Reuters) -Pfizer said on Friday it has received an early clearance from the U.S. Federal Trade Commission for its proposed acquisition of Metsera, removing a key regulatory hurdle for the deal valued at up to $7.3 billion. The FTC granted early termination of the waiting period required under the Hart-Scott-Rodino Act, which governs antitrust reviews of large mergers. The waiting period was originally set to expire on November 7. The clearance means Pfizer can move ahead with its proposed purchase of Metsera without further antitrust review from U.S. regulators. Shares of Pfizer closed about 1.5% higher on Friday. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
VIDEO SHOWS: FILE FOOTAGE OF JEAN-LOUIS GASSET SHOWS: LISBON, PORTUGAL (FILE – APRIL 10, 2024)…
By Sruthi Shankar and Shashwat Chauhan Dec 26 (Reuters) - Wall Street indexes were poised…
By Eduardo Baptista BEIJING, Dec 26 (Reuters) - Chinese companies developing reusable commercial rockets will…
Mumbai (Maharashtra) [India], December 25: Holani Consultants Private Limited has achieved an unprecedented milestone in…
From L to R Mr. Mukesh Patel, MD and Mr. Kamlesh Patel, CMD, Asian Granito…
New Delhi [India], December 26: The National Association of Realtors–India (NAR-INDIA) closed 2025 with a…